Literature DB >> 27182213

European Experience of Infliximab Biosimilars for the Treatment of Inflammatory Bowel Disease.

Peter Lakatos1.   

Abstract

Entities:  

Year:  2016        PMID： 27182213      PMCID： PMC4865772     

Source DB:  PubMed          Journal:  Gastroenterol Hepatol (N Y)        ISSN： 1554-7914


× No keyword cloud information.
  8 in total

1.  Post-marketing study of biosimilar infliximab (CT-P13) to evaluate its safety and efficacy in Korea.

Authors:  Sang Hyoung Park; Young-Ho Kim; Ji Hyun Lee; Hyeok Jin Kwon; Suck-Ho Lee; Dong Il Park; Hyung Kil Kim; Jae Hee Cheon; Jong Pil Im; You Sun Kim; Sung Young Lee; Sang Joon Lee
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2015       Impact factor: 3.869

2.  Switching Between Infliximab Originator and Biosimilar in Paediatric Patients with Inflammatory Bowel Disease. Preliminary Observations.

Authors:  J Sieczkowska; D Jarzębicka; A Banaszkiewicz; A Plocek; A Gawronska; E Toporowska-Kowalska; G Oracz; M Meglicka; J Kierkus
Journal:  J Crohns Colitis       Date:  2015-12-30       Impact factor: 9.071

3.  A budget impact model for biosimilar infliximab in Crohn's disease in Bulgaria, the Czech Republic, Hungary, Poland, Romania, and Slovakia.

Authors:  Valentin Brodszky; Fanni Rencz; Márta Péntek; Petra Baji; Péter L Lakatos; László Gulácsi
Journal:  Expert Rev Pharmacoecon Outcomes Res       Date:  2015-07-10       Impact factor: 2.217

4.  Biosimilar infliximab (CT-P13) in the treatment of inflammatory bowel disease: A Norwegian observational study.

Authors:  Jørgen Jahnsen; Trond Espen Detlie; Simen Vatn; Petr Ricanek
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2015       Impact factor: 3.869

5.  Efficacy of the new infliximab biosimilar CT-P13 induction therapy in Crohn's disease and ulcerative colitis - experiences from a single center.

Authors:  Klaudia Farkas; Mariann Rutka; Anita Bálint; Ferenc Nagy; Renáta Bor; Ágnes Milassin; Zoltán Szepes; Tamás Molnár
Journal:  Expert Opin Biol Ther       Date:  2015-07-02       Impact factor: 4.388

6.  Treatment preferences of originator versus biosimilar drugs in Crohn's disease; discrete choice experiment among gastroenterologists.

Authors:  Petra Baji; László Gulácsi; Barbara D Lovász; Petra A Golovics; Valentin Brodszky; Márta Péntek; Fanni Rencz; Péter L Lakatos
Journal:  Scand J Gastroenterol       Date:  2015-06-10       Impact factor: 2.423

Review 7.  A review of CT-P13: an infliximab biosimilar.

Authors:  Kate McKeage
Journal:  BioDrugs       Date:  2014-06       Impact factor: 5.807

8.  Efficacy and Safety of the Biosimilar Infliximab CT-P13 Treatment in Inflammatory Bowel Diseases: A Prospective, Multicentre, Nationwide Cohort.

Authors:  Krisztina B Gecse; Barbara D Lovász; Klaudia Farkas; János Banai; László Bene; Beáta Gasztonyi; Petra Anna Golovics; Tünde Kristóf; László Lakatos; Ágnes Anna Csontos; Márk Juhász; Ferenc Nagy; Károly Palatka; Mária Papp; Árpád Patai; Lilla Lakner; Ágnes Salamon; Tamás Szamosi; Zoltán Szepes; Gábor T Tóth; Áron Vincze; Balázs Szalay; Tamás Molnár; Péter L Lakatos
Journal:  J Crohns Colitis       Date:  2015-12-10       Impact factor: 9.071
  8 in total
  2 in total

1.  Economic Impact of Non-Medical Switching from Originator Biologics to Biosimilars: A Systematic Literature Review.

Authors:  Yifei Liu; Min Yang; Vishvas Garg; Eric Q Wu; Jessie Wang; Martha Skup
Journal:  Adv Ther       Date:  2019-06-05       Impact factor: 3.845

Review 2.  The Future of Biosimilars: Maximizing Benefits Across Immune-Mediated Inflammatory Diseases.

Authors:  HoUng Kim; Rieke Alten; Luisa Avedano; Axel Dignass; Fernando Gomollón; Kay Greveson; Jonas Halfvarson; Peter M Irving; Jørgen Jahnsen; Péter L Lakatos; JongHyuk Lee; Souzi Makri; Ben Parker; Laurent Peyrin-Biroulet; Stefan Schreiber; Steven Simoens; Rene Westhovens; Silvio Danese; Ji Hoon Jeong
Journal:  Drugs       Date:  2020-02       Impact factor: 9.546
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.